FOXM1 and plasma cell myeloma: The main finding of this study is the demonstration that (1) FOXM1 prognosticates inferior survival of patients with myeloma in the MMRF CoMMpass trial (NCT01454297); (2) FOXM1 is a positive regulator of myeloma metabolism with major impact on glycolysis and cellular respiration; (3) the novel small-compound FOXM1 inhibitor, NB73, slows down myeloma; (4) the heat shock protein 90 (HSP90) inhibitor, GDA, cooperates with NB73 in down regulating FOXM1 and suppressing myeloma.